Skip to main content
Top
Published in: Hepatology International 3/2021

01-06-2021 | Endoscopy | Editorial

A community of portal hypertension

Authors: Xiaolong Qi, Yifei Huang, Michael Pavlides, Don C. Rockey

Published in: Hepatology International | Issue 3/2021

Login to get access

Excerpt

Portal hypertension is an important, if not the most important, factor affecting the clinical course of patients with cirrhosis, as it can predict the development of cirrhosis-related complications, such as variceal bleeding, ascites, and hepatic encephalopathy [13]. The management of portal hypertension should cover early screening and detection, primary prevention of complications, emergency care for variceal bleeding, and secondary prevention. Here, we propose a concept termed “A Community of Portal Hypertension” (Fig. 1), emphasizing multidisciplinary team (MDT)-oriented practice, innovation-oriented research, and patient-oriented care, to promote comprehensive management of portal hypertension.
Literature
1.
go back to reference Sun X, Zhang A, Zhou T, et al. Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial. Hepatol Int 2021. Epub ahead of print. Sun X, Zhang A, Zhou T, et al. Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial. Hepatol Int 2021. Epub ahead of print.
2.
go back to reference de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.CrossRef de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.CrossRef
3.
go back to reference Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–35.CrossRef Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–35.CrossRef
4.
go back to reference Taylor C, Munro AJ, Glynne-Jones R, et al. Multidisciplinary team working in cancer: what is the evidence? BMJ. 2010;340:c951.CrossRef Taylor C, Munro AJ, Glynne-Jones R, et al. Multidisciplinary team working in cancer: what is the evidence? BMJ. 2010;340:c951.CrossRef
5.
go back to reference Chinai N, Bintcliffe F, Armstrong EM, et al. Does every patient need to be discussed at a multidisciplinary team meeting? Clin Radiol. 2013;68:780–4.CrossRef Chinai N, Bintcliffe F, Armstrong EM, et al. Does every patient need to be discussed at a multidisciplinary team meeting? Clin Radiol. 2013;68:780–4.CrossRef
6.
go back to reference Tseng Y, Ma L, Lv M, et al. The role of a multidisciplinary team in the management of portal hypertension. BMC Gastroenterol. 2020;20:83.CrossRef Tseng Y, Ma L, Lv M, et al. The role of a multidisciplinary team in the management of portal hypertension. BMC Gastroenterol. 2020;20:83.CrossRef
8.
go back to reference James L, Yuanyuan Y, Raymond T, et al. Timing of endoscopy for acute upper gastrointestinal bleeding. N Engl J Med. 2020;382:1299–308.CrossRef James L, Yuanyuan Y, Raymond T, et al. Timing of endoscopy for acute upper gastrointestinal bleeding. N Engl J Med. 2020;382:1299–308.CrossRef
9.
go back to reference Liu Y, Ning Z, Ormeci N, et al. Deep convolutional neural network-aided detection of portal hypertension in patients with cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2998–3007.CrossRef Liu Y, Ning Z, Ormeci N, et al. Deep convolutional neural network-aided detection of portal hypertension in patients with cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2998–3007.CrossRef
10.
go back to reference Qi X, An W, Liu F, et al. Virtual hepatic venous pressure gradient with ct angiography (CHESS 1601): a prospective multicenter study for the noninvasive diagnosis of portal hypertension. Radiology. 2019;290:370–7.CrossRef Qi X, An W, Liu F, et al. Virtual hepatic venous pressure gradient with ct angiography (CHESS 1601): a prospective multicenter study for the noninvasive diagnosis of portal hypertension. Radiology. 2019;290:370–7.CrossRef
11.
go back to reference Levick C, Phillips-Hughes J, Collier J, et al. Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: a proof of concept study. PLoS ONE. 2019;14:e0221066.CrossRef Levick C, Phillips-Hughes J, Collier J, et al. Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: a proof of concept study. PLoS ONE. 2019;14:e0221066.CrossRef
12.
go back to reference Qi X, Li Z, Huang J, et al. Virtual portal pressure gradient from anatomic CT angiography. Gut. 2015;64:1004–5.CrossRef Qi X, Li Z, Huang J, et al. Virtual portal pressure gradient from anatomic CT angiography. Gut. 2015;64:1004–5.CrossRef
13.
go back to reference Liu F, Ning Z, Liu Y, et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. EBioMedicine. 2018;36:151–8.CrossRef Liu F, Ning Z, Liu Y, et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. EBioMedicine. 2018;36:151–8.CrossRef
14.
go back to reference Qi X, Berzigotti A, Cardenas A, Sarin S. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018;3:708–19.CrossRef Qi X, Berzigotti A, Cardenas A, Sarin S. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018;3:708–19.CrossRef
15.
go back to reference Wang S, Huang Y, Hu W, et al. Detachable string magnetically controlled capsule endoscopy for detecting high-risk varices in compensated advanced chronic liver disease (CHESS1801): a prospective multicenter study. The Lancet. 2021;9:19–23. Wang S, Huang Y, Hu W, et al. Detachable string magnetically controlled capsule endoscopy for detecting high-risk varices in compensated advanced chronic liver disease (CHESS1801): a prospective multicenter study. The Lancet. 2021;9:19–23.
16.
go back to reference Hayley H, Wai-Yee C, Laith A, et al. Development and validation of the gastrointestinal endoscopy satisfaction questionnaire (GESQ). Endoscopy. 2015;47:1137–43.CrossRef Hayley H, Wai-Yee C, Laith A, et al. Development and validation of the gastrointestinal endoscopy satisfaction questionnaire (GESQ). Endoscopy. 2015;47:1137–43.CrossRef
17.
go back to reference Neuberger J, Bryan S. Clinical economics review: cost-effectiveness in the therapy of liver disease. Aliment Pharmacol Ther. 1997;11:61–8.CrossRef Neuberger J, Bryan S. Clinical economics review: cost-effectiveness in the therapy of liver disease. Aliment Pharmacol Ther. 1997;11:61–8.CrossRef
Metadata
Title
A community of portal hypertension
Authors
Xiaolong Qi
Yifei Huang
Michael Pavlides
Don C. Rockey
Publication date
01-06-2021
Publisher
Springer India
Published in
Hepatology International / Issue 3/2021
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10192-9

Other articles of this Issue 3/2021

Hepatology International 3/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine